EPID_Separ
121 posts
@EPID_Separ
Perfil oficial del Grupo de Enfermedades Pulmonares Intersticiales de SEPAR 🫁 Official account of the SEPAR Interstitial Lung Diseases Group 🇪🇸
In the phase 3 TETON-2 trial involving patients with idiopathic pulmonary fibrosis, inhaled treprostinil was associated with a smaller decline in forced vital capacity and a lower risk of clinical worsening than placebo over 52 weeks. Full trial results: nejm.org/doi/full/10.10…
🫁𝐍𝐚𝐥𝐛𝐮𝐟𝐢𝐧𝐚 𝐨𝐫𝐚𝐥 𝐞𝐧 𝐥𝐚 𝐭𝐨𝐬 𝐚𝐬𝐨𝐜𝐢𝐚𝐝𝐚 𝐚 𝐥𝐚 𝐟𝐢𝐛𝐫𝐨𝐬𝐢𝐬 𝐩𝐮𝐥𝐦𝐨𝐧𝐚𝐫 𝐢𝐝𝐢𝐨𝐩𝐚́𝐭𝐢𝐜𝐚 𝐄𝐥 𝐞𝐧𝐬𝐚𝐲𝐨 𝐜𝐥𝐢́𝐧𝐢𝐜𝐨 𝐚𝐥𝐞𝐚𝐭𝐨𝐫𝐢𝐳𝐚𝐝𝐨 𝐂𝐎𝐑𝐀𝐋 🔸Nalbufina ER 27 mg, 54 mg y 108 mg dos x al día 🔸Redujo en un 47,9%, 53,4% y 60,2%, respectivamente, en comparación con placebo (16,9%) en el seguimiento de 6 semanas. 🚩tinyurl.com/36ebbjea ♦️Resumen IA tinyurl.com/4dpuywtu ''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''' @twitaamr @LancetRespirMed @EpocEspana @apepoc_es @NeumoMadrid @CNC_SATI @RespiraINER @enfisema @ForodeMedicina @ForoFIMI @NeumologiaPT @ClinicaDrC @DrCormi @SEAIC_Alergia @vacunasalergia @SocLatAlergia @alergia @aaoncoclinica @saom_oncologia @CardiOncoSAC @Oncologia @UBAonline @UBARectorado @UBAMedicina @ReSaludable @FacMedicinaUNAM @ANacionalMed @Medicina_TV @MedicinaSAM @porqueTTarg @AgenciaElVigia @aleberco @JTartaglione @FioTartaglione @adrocormillot
🫁 Complex HRCT Case Male, 49 years, ex-smoker Admitted with chest infection. HRCT video below 👇 What is your impression regarding the smoking-related lung disease component on this scan? Looking forward to your thoughts. I will share the detailed analysis in the comments after your responses.
💊🛡️🫁 Methotrexate & the RA Lung: Not the Villain after all? Systematic Review 🎯 Objectives •🔍 Assess progression of RA-ILD in patients exposed to methotrexate (MTX) •🫁 Evaluate lung involvement in RA patients without ILD who are exposed to MTX 🧪 Methods •📚 Systematic review of studies reporting MTX effects on ILD (primary or secondary endpoints) •👥 36,444 RA patients •💉 18,548 (50.8%) on MTX •🆚 Non-MTX users (N-MTX) used as controls in 14 studies 🔬 Lung assessment tools •🖥️ HRCT: 10 studies •🌬️ PFTs: 8 studies •🩸 ABG analysis: 1 study •⏳ Survival analysis: 5 studies 📌 Key Results 1️⃣ MTX & ILD Development •🛡️ 9 studies: MTX not associated with developing ILD 2️⃣ MTX & RA-ILD Progression •📘 5 studies: MTX not associated with ILD progression •⚠️ 1 study: Low-dose MTX → accelerated decline in lung function 3️⃣ Survival •💙 1 study: MTX group had better survival vs N-MTX 4️⃣ Acute Exacerbations •❗ 1 study: MTX significantly associated with acute ILD exacerbations 🧾 Conclusion MTX shows no overall association with increased risk or progression of ILD in RA patients. Conflicting findings exist regarding lung function decline and acute exacerbations, but the predominant evidence supports MTX safety in RA-ILD. #RheumattDoc #MedTwitter #BSR #RheumTwitter #rheumatology @DrAkhilX @IhabFathiSulima @CelestinoGutirr @DurgaPrasannaM1 @nileshnolkha
